NASDAQ · MTSR

Metsera, Inc.

Healthcare · Biotechnology

$70.50▼ 0.35% ($0.25)at close

As of 4:00 PM ET

52-week

$12.30$83.86

Market cap

$7.43B

P/E

-28.09

Volume

27.87M

Shares outstanding

105.38M

Valuation

Recommended · Earnings yield

Price used

$70.50

Earnings yield

Unavailable

Reported earnings

10-year Treasury benchmark: 4.95%

USD · Financial statements through 2025-09-30 · EPS source period not supplied

A positive earnings figure and a usable price are needed to calculate earnings yield.

Method, dates & sources

Earnings per share divided by the price used, compared with the 10-year Treasury rate.

Price timestamp: Nov 13, 2025, 9:00 PM UTC
Financial statement period: Financial statements through 2025-09-30 · EPS source period not supplied
Data refreshed: Sep 11, 2026, 1:06 AM UTC · provider

Why this method?

The company is still too young and does not have a stable, multi-year FCFF base. Use EV/Revenue multiples and comparable transactions instead of a DCF.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Is there enough operating history to anchor a DCF? Only 1 years of public or statement history are available, so multiples are more decision-useful than a DCF here.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.

1Y Price: 166.04%FCF (TTM): -200.71%

What changed

The stock rose 166.04% over the last year. Free cash flow declined 200.71% over the trailing twelve months.

What the market seems to be pricing

The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.

Performance

Monthly returns

Company profile

Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides.

CEOChristopher Whitten Bernard

SectorHealthcare

IndustryBiotechnology

Employees93

IPO dateJan 31, 2025

https://www.pfizer.com

Market multiples

Forward P/E—

EV/EBITDA-10.94

Enterprise value$2.39B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth—

Gross margin0%

Operating margin0%

ROE-134.66%▼26.3ppvs FY2024

Analyst consensus

RatingBuy

Target price$55.50▼21.28%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Mar 25, 2026

Q1 FY26 · EPS est -$0.54 · Revenue est —

View